News & Updates

Immune changes, persistent spike protein seen in people with PVS

06 Mar 2025 by

People with post-vaccination syndrome (PVS), a rare condition following receipt of COVID-19 jabs, exhibit distinct immunological patterns, including the reappearance of the dormant Epstein-Barr virus (EBV) and persistence of SARS-CoV-2 spike protein in the blood, according to new research.

Immune changes, persistent spike protein seen in people with PVS

06 Mar 2025

Shorter duration, larger lesion predict treatment failure with 5-FU 5% cream

05 Mar 2025

Treatment with 5-fluorouracil (5-FU) 5% cream tends to end in failure with shorter treatment duration and larger lesion size in patients with squamous cell carcinoma in situ (SCCis), a study has shown.

Shorter duration, larger lesion predict treatment failure with 5-FU 5% cream

05 Mar 2025

EV-302 2-year updates: EV+P maintains transformative benefit in bladder cancer

05 Mar 2025 by

The updated analysis of the phase III EV-302 trial continues to show the benefit of front-line enfortumab vedotin plus pembrolizumab (EV+P) compared with chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).

EV-302 2-year updates: EV+P maintains transformative benefit in bladder cancer

05 Mar 2025

No cardiovascular signal with anti-CGRP mAbs for migraine

05 Mar 2025

Migraine treatment with monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) or its receptor does not appear to contribute to increased risk of cardiovascular disease (CVD) compared with onabotulinumtoxinA in adults, including those who are older and with disability, according to a retrospective cohort study.

No cardiovascular signal with anti-CGRP mAbs for migraine

05 Mar 2025

Frontline nivolumab plus ipilimumab ups OS, ORR in patients with uHCC

05 Mar 2025 by

The combination of nivolumab and ipilimumab (NIVO + IPI) significantly improves overall survival (OS) and objective response rate (ORR) compared with lenvatinib or sorafenib (LEN/SOR) in the first-line setting for patients with unresectable hepatocellular carcinoma (uHCC), based on the CheckMate 9DW expanded analyses presented at ASCO GI 2025.

Frontline nivolumab plus ipilimumab ups OS, ORR in patients with uHCC

05 Mar 2025

De-escalating ticagrelor monotherapy reduces bleeding in ACS

04 Mar 2025

De-escalation of dual antiplatelet therapy (DAPT) to ticagrelor monotherapy results in a decreased risk for major bleeding compared with standard DAPT among patients with acute coronary syndrome (ACS) undergoing drug-eluting stent (DES) implantation, reports a study.

De-escalating ticagrelor monotherapy reduces bleeding in ACS

04 Mar 2025

MERLIN: Brolucizumab not inferior to aflibercept in nAMD

04 Mar 2025 by

Two-year treatment with brolucizumab 6 mg every 4 weeks demonstrates noninferiority in mean best-corrected visual acuity (BCVA), with superior anatomic outcomes, to aflibercept 2 mg every 4 weeks in patients with neovascular age-related macular degeneration (nAMD), as shown in the MERLIN study.

MERLIN: Brolucizumab not inferior to aflibercept in nAMD

04 Mar 2025

Oestradiol patches bump up ADT armamentarium for prostate cancer

04 Mar 2025 by

Findings from a phase II trial demonstrate the potential of transdermal oestradiol (tE2) patches as androgen deprivation therapy (ADT) for men with metastatic (M1) prostate cancer who are on androgen receptor pathway inhibitors (ARPI).

Oestradiol patches bump up ADT armamentarium for prostate cancer

04 Mar 2025

Age does not influence ferric derisomaltose treatment outcomes

03 Mar 2025

In the treatment of patients with heart failure with reduced ejection fraction (HFrEF) and iron deficiency, the use of ferric derisomaltose appears to result in similar outcomes across age groups, according to data from the open-label IRONMAN trial.

Age does not influence ferric derisomaltose treatment outcomes

03 Mar 2025

GLP-1RAs lower depression risk in older adults with T2D

03 Mar 2025

The incidence of depression among older adults with type 2 diabetes is low, and the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) helps reduce the risk of depression relative to dipeptidyl peptidase-4 inhibitors (DPP4is), but not sodium–glucose cotransporter-2 inhibitors (SGLT2is).

GLP-1RAs lower depression risk in older adults with T2D

03 Mar 2025

News & Updates

Filter by Specialty:

Specialty:

Immune changes, persistent spike protein seen in people with PVS

Immune changes, persistent spike protein seen in people with PVS

Shorter duration, larger lesion predict treatment failure with 5-FU 5% cream

Shorter duration, larger lesion predict treatment failure with 5-FU 5% cream

EV-302 2-year updates: EV+P maintains transformative benefit in bladder cancer

EV-302 2-year updates: EV+P maintains transformative benefit in bladder cancer

No cardiovascular signal with anti-CGRP mAbs for migraine

No cardiovascular signal with anti-CGRP mAbs for migraine

Frontline nivolumab plus ipilimumab ups OS, ORR in patients with uHCC

Frontline nivolumab plus ipilimumab ups OS, ORR in patients with uHCC

De-escalating ticagrelor monotherapy reduces bleeding in ACS

De-escalating ticagrelor monotherapy reduces bleeding in ACS

MERLIN: Brolucizumab not inferior to aflibercept in nAMD

MERLIN: Brolucizumab not inferior to aflibercept in nAMD

Oestradiol patches bump up ADT armamentarium for prostate cancer

Oestradiol patches bump up ADT armamentarium for prostate cancer

Age does not influence ferric derisomaltose treatment outcomes

Age does not influence ferric derisomaltose treatment outcomes

GLP-1RAs lower depression risk in older adults with T2D

GLP-1RAs lower depression risk in older adults with T2D